{"id":69074,"date":"2026-06-30T11:35:58","date_gmt":"2026-06-30T03:35:58","guid":{"rendered":"https:\/\/flcube.com\/?p=69074"},"modified":"2026-06-30T11:35:59","modified_gmt":"2026-06-30T03:35:59","slug":"biocytogen-prevails-in-shanghai-ip-court-as-harbour-biomed-patent-infringement-claims-dismissed-rennano-platform-cleared-of-antibody-technology-violations","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69074","title":{"rendered":"Biocytogen Prevails in Shanghai IP Court as Harbour BioMed Patent Infringement Claims Dismissed \u2013 RenNano Platform Cleared of Antibody Technology Violations"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Biocytogen Pharmaceuticals (Beijing) Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/002173:SHE\">SHA: 688796<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/2315:HKG\">HKG: 2315<\/a>) announced it has received a favorable <strong>first-instance Civil Judgment<\/strong> from the <strong>Shanghai Intellectual Property Court<\/strong>, which ruled that the company <strong>did not infringe<\/strong> upon patent rights held by <strong>Harbour BioMed<\/strong> related to its <strong>RenNano antibody discovery platform<\/strong> and derived products.<\/p>\n\n\n\n<h2 id=\"h-legal-timeline-amp-key-developments\" class=\"wp-block-heading\">Legal Timeline &amp; Key Developments<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Date<\/th><th>Event<\/th><th>Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>Sep 4, 2024<\/strong><\/td><td>Harbour BioMed files initial lawsuit<\/td><td>Alleged RenNano platform infringed Chinese Patent ZL201210057668.0<\/td><\/tr><tr><td><strong>Jul 22, 2025<\/strong><\/td><td>Patent term expiration<\/td><td>Harbour BioMed&#8217;s involved patent (ZL201210057668.0) expired<\/td><\/tr><tr><td><strong>Aug 28, 2025<\/strong><\/td><td>First hearing terminated<\/td><td>Proceeding halted due to opposing counsel conflict of interest<\/td><\/tr><tr><td><strong>Oct 13, 2025<\/strong><\/td><td>Initial lawsuit withdrawn<\/td><td>Harbour BioMed voluntarily dismissed first case<\/td><\/tr><tr><td><strong>Nov 5, 2025<\/strong><\/td><td>New lawsuit filed<\/td><td>Harbour BioMed refiled identical claims regarding same patent<\/td><\/tr><tr><td><strong>Jan 27, 2026<\/strong><\/td><td>Second case hearing completed<\/td><td>Full evidentiary presentation and arguments concluded<\/td><\/tr><tr><td><strong>Jun 29, 2026<\/strong><\/td><td>Court rules for Biocytogen<\/td><td>All infringement claims dismissed<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-case-background-amp-technical-dispute\" class=\"wp-block-heading\">Case Background &amp; Technical Dispute<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Plaintiff<\/strong>: Harbour BioMed (exclusive licensee of Chinese Patent ZL201210057668.0)<\/li>\n\n\n\n<li><strong>Defendant<\/strong>: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.<\/li>\n\n\n\n<li><strong>Disputed Technology<\/strong>: RenNano platform and antibody products derived therefrom<\/li>\n\n\n\n<li><strong>Alleged Infringement<\/strong>: Unauthorized use of patented antibody generation methods<\/li>\n\n\n\n<li><strong>Relief Sought<\/strong>: Permanent injunction against Biocytogen&#8217;s RenNano platform operations<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The core dispute centered on whether Biocytogen&#8217;s proprietary RenNano platform\u2014which enables rapid discovery and optimization of therapeutic antibodies\u2014utilized methods covered by Harbour BioMed&#8217;s exclusively licensed patent. Despite the patent&#8217;s expiration in July 2025, Harbour BioMed pursued damages and injunctive relief for alleged past infringement during the patent&#8217;s active period.<\/p>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Platform Validation<\/strong><\/td><td>Court ruling affirms independence and non-infringing nature of RenNano technology<\/td><\/tr><tr><td><strong>Commercial Freedom<\/strong><\/td><td>Biocytogen maintains unrestricted operation of its antibody discovery platform<\/td><\/tr><tr><td><strong>Partnership Security<\/strong><\/td><td>Existing and potential partners gain confidence in platform&#8217;s intellectual property integrity<\/td><\/tr><tr><td><strong>Market Position<\/strong><\/td><td>Strengthens Biocytogen&#8217;s competitive standing in China&#8217;s rapidly growing biologics discovery market<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">China&#8217;s biologics discovery market represents a critical growth segment within the broader pharmaceutical industry, with antibody therapeutics accounting for over 40% of new drug approvals in recent years. Biocytogen&#8217;s RenNano platform serves as a cornerstone of its business model, enabling both internal pipeline development and external partnerships with global pharmaceutical companies.<\/p>\n\n\n\n<h2 id=\"h-forward-outlook-amp-appeal-process\" class=\"wp-block-heading\">Forward Outlook &amp; Appeal Process<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Despite the favorable first-instance ruling, <strong>Harbour BioMed has announced its intention to appeal<\/strong> to the <strong>Supreme People&#8217;s Court<\/strong>, citing alleged errors in the lower court&#8217;s determination of technical facts. The appeal process is expected to extend through 2027, though the current judgment remains enforceable pending final resolution.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Biocytogen maintains that its RenNano platform represents independently developed innovation protected by its own extensive patent portfolio, which includes over 200 issued patents globally covering various aspects of its antibody discovery technologies.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Market Reaction<\/strong>: Biocytogen shares rose 4.2% in Shanghai trading following the announcement, reflecting investor confidence in the company&#8217;s intellectual property position and continued platform operations.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding legal proceedings and business implications. Actual outcomes may differ due to risks including appellate court decisions, regulatory changes, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/688796_20260630_RGLK.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688796_20260630_RGLK.\"><\/object><a id=\"wp-block-file--media-3392d4a6-8438-43ee-9d5f-33e40acef6f6\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/688796_20260630_RGLK.pdf\">688796_20260630_RGLK<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/688796_20260630_RGLK.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-3392d4a6-8438-43ee-9d5f-33e40acef6f6\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315) announced it has received a favorable&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[61],"tags":[1519,1214,73,4547],"class_list":["post-69074","post","type-post","status-publish","format-standard","hentry","category-legal-ip","tag-biocytogen-pharmaceuticals","tag-hkg-2315","tag-patents","tag-sha-688796"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Biocytogen Prevails in Shanghai IP Court as Harbour BioMed Patent Infringement Claims Dismissed \u2013 RenNano Platform Cleared of Antibody Technology Violations - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315) announced it has received a favorable first-instance Civil Judgment from the Shanghai Intellectual Property Court, which ruled that the company did not infringe upon patent rights held by Harbour BioMed related to its RenNano antibody discovery platform and derived products.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69074\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biocytogen Prevails in Shanghai IP Court as Harbour BioMed Patent Infringement Claims Dismissed \u2013 RenNano Platform Cleared of Antibody Technology Violations\" \/>\n<meta property=\"og:description\" content=\"Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315) announced it has received a favorable first-instance Civil Judgment from the Shanghai Intellectual Property Court, which ruled that the company did not infringe upon patent rights held by Harbour BioMed related to its RenNano antibody discovery platform and derived products.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69074\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-30T03:35:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-30T03:35:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69074#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69074\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Biocytogen Prevails in Shanghai IP Court as Harbour BioMed Patent Infringement Claims Dismissed \u2013 RenNano Platform Cleared of Antibody Technology Violations\",\"datePublished\":\"2026-06-30T03:35:58+00:00\",\"dateModified\":\"2026-06-30T03:35:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69074\"},\"wordCount\":508,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biocytogen Pharmaceuticals\",\"HKG: 2315\",\"Patents\",\"SHA: 688796\"],\"articleSection\":[\"Legal \\\/ IP\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69074#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69074\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69074\",\"name\":\"Biocytogen Prevails in Shanghai IP Court as Harbour BioMed Patent Infringement Claims Dismissed \u2013 RenNano Platform Cleared of Antibody Technology Violations - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-30T03:35:58+00:00\",\"dateModified\":\"2026-06-30T03:35:59+00:00\",\"description\":\"Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315) announced it has received a favorable first-instance Civil Judgment from the Shanghai Intellectual Property Court, which ruled that the company did not infringe upon patent rights held by Harbour BioMed related to its RenNano antibody discovery platform and derived products.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69074#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69074\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69074#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biocytogen Prevails in Shanghai IP Court as Harbour BioMed Patent Infringement Claims Dismissed \u2013 RenNano Platform Cleared of Antibody Technology Violations\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Biocytogen Prevails in Shanghai IP Court as Harbour BioMed Patent Infringement Claims Dismissed \u2013 RenNano Platform Cleared of Antibody Technology Violations - Insight, China&#039;s Pharmaceutical Industry","description":"Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315) announced it has received a favorable first-instance Civil Judgment from the Shanghai Intellectual Property Court, which ruled that the company did not infringe upon patent rights held by Harbour BioMed related to its RenNano antibody discovery platform and derived products.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69074","og_locale":"en_US","og_type":"article","og_title":"Biocytogen Prevails in Shanghai IP Court as Harbour BioMed Patent Infringement Claims Dismissed \u2013 RenNano Platform Cleared of Antibody Technology Violations","og_description":"Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315) announced it has received a favorable first-instance Civil Judgment from the Shanghai Intellectual Property Court, which ruled that the company did not infringe upon patent rights held by Harbour BioMed related to its RenNano antibody discovery platform and derived products.","og_url":"https:\/\/flcube.com\/?p=69074","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-30T03:35:58+00:00","article_modified_time":"2026-06-30T03:35:59+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69074#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69074"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Biocytogen Prevails in Shanghai IP Court as Harbour BioMed Patent Infringement Claims Dismissed \u2013 RenNano Platform Cleared of Antibody Technology Violations","datePublished":"2026-06-30T03:35:58+00:00","dateModified":"2026-06-30T03:35:59+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69074"},"wordCount":508,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biocytogen Pharmaceuticals","HKG: 2315","Patents","SHA: 688796"],"articleSection":["Legal \/ IP"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69074#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69074","url":"https:\/\/flcube.com\/?p=69074","name":"Biocytogen Prevails in Shanghai IP Court as Harbour BioMed Patent Infringement Claims Dismissed \u2013 RenNano Platform Cleared of Antibody Technology Violations - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-30T03:35:58+00:00","dateModified":"2026-06-30T03:35:59+00:00","description":"Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315) announced it has received a favorable first-instance Civil Judgment from the Shanghai Intellectual Property Court, which ruled that the company did not infringe upon patent rights held by Harbour BioMed related to its RenNano antibody discovery platform and derived products.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69074#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69074"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69074#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Biocytogen Prevails in Shanghai IP Court as Harbour BioMed Patent Infringement Claims Dismissed \u2013 RenNano Platform Cleared of Antibody Technology Violations"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69074","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69074"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69074\/revisions"}],"predecessor-version":[{"id":69076,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69074\/revisions\/69076"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69074"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69074"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69074"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}